Tenaya Therapeutics (TNYA) Competitors $1.14 -0.13 (-9.92%) As of 03:23 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TNYA vs. DNA, ATAI, SANA, NAGE, TNGX, BGM, OCS, AVBP, NRIX, and GYREShould you be buying Tenaya Therapeutics stock or one of its competitors? The main competitors of Tenaya Therapeutics include Ginkgo Bioworks (DNA), atai Life Sciences (ATAI), Sana Biotechnology (SANA), Niagen Bioscience (NAGE), Tango Therapeutics (TNGX), BGM Group (BGM), Oculis (OCS), ArriVent BioPharma (AVBP), Nurix Therapeutics (NRIX), and Gyre Therapeutics (GYRE). These companies are all part of the "pharmaceutical products" industry. Tenaya Therapeutics vs. Its Competitors Ginkgo Bioworks atai Life Sciences Sana Biotechnology Niagen Bioscience Tango Therapeutics BGM Group Oculis ArriVent BioPharma Nurix Therapeutics Gyre Therapeutics Tenaya Therapeutics (NASDAQ:TNYA) and Ginkgo Bioworks (NYSE:DNA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends. Do institutionals and insiders hold more shares of TNYA or DNA? 90.5% of Tenaya Therapeutics shares are owned by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are owned by institutional investors. 48.7% of Tenaya Therapeutics shares are owned by insiders. Comparatively, 9.7% of Ginkgo Bioworks shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media prefer TNYA or DNA? In the previous week, Tenaya Therapeutics had 3 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 6 mentions for Tenaya Therapeutics and 3 mentions for Ginkgo Bioworks. Tenaya Therapeutics' average media sentiment score of 0.38 beat Ginkgo Bioworks' score of 0.05 indicating that Tenaya Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenaya Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ginkgo Bioworks 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, TNYA or DNA? Tenaya Therapeutics has a beta of 3.01, indicating that its share price is 201% more volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Which has better earnings and valuation, TNYA or DNA? Tenaya Therapeutics has higher earnings, but lower revenue than Ginkgo Bioworks. Ginkgo Bioworks is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTenaya TherapeuticsN/AN/A-$111.13M-$0.96-1.18Ginkgo Bioworks$227.04M3.16-$547.03M-$5.86-2.07 Do analysts prefer TNYA or DNA? Tenaya Therapeutics currently has a consensus price target of $6.25, suggesting a potential upside of 450.66%. Ginkgo Bioworks has a consensus price target of $8.50, suggesting a potential downside of 29.93%. Given Tenaya Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Tenaya Therapeutics is more favorable than Ginkgo Bioworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tenaya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Ginkgo Bioworks 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Is TNYA or DNA more profitable? Tenaya Therapeutics has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -136.56%. Ginkgo Bioworks' return on equity of -43.25% beat Tenaya Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tenaya TherapeuticsN/A -93.83% -75.66% Ginkgo Bioworks -136.56%-43.25%-22.29% SummaryTenaya Therapeutics beats Ginkgo Bioworks on 12 of the 15 factors compared between the two stocks. Get Tenaya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TNYA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TNYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TNYA vs. The Competition Export to ExcelMetricTenaya TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$183.35M$3.07B$5.76B$9.64BDividend YieldN/A2.22%3.91%4.09%P/E Ratio-1.1720.4230.8225.11Price / SalesN/A356.30457.82117.10Price / CashN/A41.5625.2228.45Price / Book1.069.569.405.96Net Income-$111.13M-$54.74M$3.26B$265.46M7 Day Performance49.93%2.68%2.07%1.08%1 Month Performance29.40%4.91%3.92%2.66%1 Year Performance-61.53%9.55%29.08%20.32% Tenaya Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TNYATenaya Therapeutics3.3598 of 5 stars$1.14-9.9%$6.25+450.7%-56.4%$183.35MN/A-1.17110Gap UpHigh Trading VolumeDNAGinkgo Bioworks1.1065 of 5 stars$13.79+4.6%$8.50-38.4%N/A$816.37M$227.04M-2.35640ATAIatai Life Sciences3.0217 of 5 stars$4.05+4.4%$11.25+177.8%+232.0%$811.37M$2.31M-5.8780Earnings ReportSANASana Biotechnology3.2221 of 5 stars$3.40+2.1%$8.00+135.3%-31.9%$808.55MN/A-3.21380NAGENiagen Bioscience1.3534 of 5 stars$10.12+1.0%$13.42+32.6%N/A$807.07M$99.60M48.19120Analyst UpgradeTNGXTango Therapeutics1.9461 of 5 stars$7.22+6.6%$10.33+43.1%-27.5%$803.30M$42.07M-5.4390Positive NewsAnalyst ForecastBGMBGM GroupN/A$8.15+7.7%N/A+47.9%$792.34M$25.10M0.00298OCSOculis2.9773 of 5 stars$18.06+0.9%$35.33+95.6%+52.3%$788.54MN/A-6.842News CoverageUpcoming EarningsShort Interest ↓AVBPArriVent BioPharma2.2189 of 5 stars$19.24-1.5%$39.14+103.4%-21.0%$780.57MN/A-4.7940NRIXNurix Therapeutics2.6153 of 5 stars$10.20-3.6%$28.87+183.0%-54.2%$779.79M$54.55M-3.91300Positive NewsHigh Trading VolumeGYREGyre Therapeutics0.0823 of 5 stars$7.85-3.6%N/A-27.9%$756.03M$105.76M785.7940 Related Companies and Tools Related Companies Ginkgo Bioworks Competitors atai Life Sciences Competitors Sana Biotechnology Competitors Niagen Bioscience Competitors Tango Therapeutics Competitors BGM Group Competitors Oculis Competitors ArriVent BioPharma Competitors Nurix Therapeutics Competitors Gyre Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TNYA) was last updated on 8/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredFormer CIA Officer Reveals How Gold Saved His Life This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenaya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenaya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access